CTSO Cytosorbents Corp
Price (delayed)
$1
Market cap
$62.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.38
Enterprise value
$79.18M
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the
Highlights
Cytosorbents's revenue has increased by 15% YoY and by 10% QoQ
The gross profit rose by 14% year-on-year and by 8% since the previous quarter
CTSO's EPS is up by 42% YoY but it is down by 2.7% from the previous quarter
CTSO's net income is up by 29% year-on-year but it is down by 7% since the previous quarter
The equity has dropped by 53% year-on-year and by 15% since the previous quarter
The debt has increased by 47% year-on-year
Key stats
What are the main financial stats of CTSO
Market
Valuations
Earnings
Shares outstanding
62.5M
Market cap
$62.5M
Enterprise value
$79.18M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.92
Price to sales (P/S)
1.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.22
Revenue
$35.59M
Gross profit
$25.13M
Operating income
-$16.79M
Net income
-$20.72M
EBIT
-$21.01M
EBITDA
-$19.27M
Free cash flow
-$14.71M
Per share
Balance sheet
Liquidity
EPS
-$0.38
EPS diluted
-$0.38
Free cash flow per share
-$0.27
Book value per share
$0.2
Revenue per share
$0.65
TBVPS
$0.87
Total assets
$47.37M
Total liabilities
$36.26M
Debt
$26.44M
Equity
$11.11M
Working capital
$11.78M
Debt to equity
2.38
Current ratio
2.2
Quick ratio
1.74
Net debt/EBITDA
-0.87
Margins
Efficiency
Dividend
EBITDA margin
-54.1%
Gross margin
70.6%
Net margin
-58.2%
Operating margin
-47.2%
Return on assets
-42.4%
Return on equity
-138.7%
Return on invested capital
-41.4%
Return on capital employed
-56%
Return on sales
-59%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTSO stock price
How has the Cytosorbents stock price performed over time
Intraday
0%
1 week
-1.96%
1 month
-5.66%
1 year
4.71%
YTD
9.89%
QTD
0%
Financial performance
How have Cytosorbents's revenue and profit performed over time
Revenue
$35.59M
Gross profit
$25.13M
Operating income
-$16.79M
Net income
-$20.72M
Gross margin
70.6%
Net margin
-58.2%
Cytosorbents's operating margin has surged by 54% YoY and by 33% QoQ
CTSO's operating income is up by 47% year-on-year and by 26% since the previous quarter
The net margin has increased by 38% year-on-year and by 2.7% since the previous quarter
CTSO's net income is up by 29% year-on-year but it is down by 7% since the previous quarter
Growth
What is Cytosorbents's growth rate over time
Valuation
What is Cytosorbents stock price valuation
P/E
N/A
P/B
4.92
P/S
1.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.22
CTSO's EPS is up by 42% YoY but it is down by 2.7% from the previous quarter
The equity has dropped by 53% year-on-year and by 15% since the previous quarter
CTSO's P/B is 26% higher than its last 4 quarters average of 3.9 and 14% higher than its 5-year quarterly average of 4.3
The stock's price to sales (P/S) is 66% less than its 5-year quarterly average of 4.5 and 10% less than its last 4 quarters average of 1.7
Cytosorbents's revenue has increased by 15% YoY and by 10% QoQ
Efficiency
How efficient is Cytosorbents business performance
The ROIC has grown by 40% YoY
CTSO's ROS is up by 39% YoY
The ROE has contracted by 29% from the previous quarter and by 13% YoY
The ROA has increased by 24% YoY but it has decreased by 10% QoQ
Dividends
What is CTSO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTSO.
Financial health
How did Cytosorbents financials performed over time
The company's total assets is 31% higher than its total liabilities
Cytosorbents's total liabilities has increased by 23% YoY and by 4.2% QoQ
The quick ratio is down by 22% QoQ but it is up by 13% YoY
The debt is 138% greater than the equity
The equity has dropped by 53% year-on-year and by 15% since the previous quarter
The debt has increased by 47% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.